PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Negative net income growth while Biotechnology median is 1.66%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
22.78%
D&A growth of 22.78% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth of 128.24% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-92.68%
Working capital is shrinking yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
AP growth of 314.60% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
26.98%
Growth of 26.98% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-101.99%
Other non-cash items dropping yoy while Biotechnology median is -1.18%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-120.47%
Negative CFO growth while Biotechnology median is 0.04%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
72.96%
CapEx growth of 72.96% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
Investing flow of 72.96% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
86.96%
Debt repayment growth of 86.96% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-90.54%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.